On October 7, 2024 HiFiBiO Therapeutics, a clinical stage immune modulation biotechnology company reported its participation in the 2024 Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), taking place November 6-10 in Houston, Texas (Press release, HiFiBiO Therapeutics, OCT 7, 2024, View Source [SID1234647055]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The company will present a pioneering clinical development strategy, showcasing the predictive power of its Drug Intelligence Science (DIS) platform to guide the Phase I development of two novel monoclonal antibodies: a first-in-class TNFR2 agonist HFB200301 (NCT05238883) and a best-in-class BTLA antagonist HFB200603 (NCT05789069). DIS provides a single cell and AI/ML-driven approach to selecting the most promising tumor types, dose regimen, and patient population for clinical success.
HiFiBiO’s unique DIS approach enables the translation of complex clinical data including patient history, imaging, PK/PD, and genomic sequencing into meaningful patient selection strategies for enhanced clinical benefit. This patient-data guided translational strategy demonstrates the company’s deep commitment to innovative research and impactful therapies to address the highest unmet medical needs.
Details on the poster presentations are as follows:
Title: Predictive and Generative AI to guide the clinical development of HFB200301, a first-in-class TNFR2 agonist: Drug Intelligence Science (DIS).
Abstract Number: 1233
Session Date: Friday, 8 November 2024
Speaker: Spencer Huggett, PhD, HiFiBiO Inc.
Title: Utilizing Drug Intelligence Science (DIS) for tumor type selection and molecular characterization of HFB200603, a best-in-class B and T Lymphocyte Attenuator (BTLA) monoclonal antagonist.
Abstract Number: 1224
Session Date: Saturday, 9 November 2024
Speaker: Spencer Huggett, PhD, HiFiBiO Inc.
The initial data from these abstracts will be available on the SITC (Free SITC Whitepaper) website starting on November 5 at 9 am EST. Additionally, the posters will be accessible on the HiFiBiO Therapeutics website following the live presentation.